<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00047697</url>
  </required_header>
  <id_info>
    <org_study_id>R21MH064941</org_study_id>
    <secondary_id>R21MH064941</secondary_id>
    <secondary_id>DSIR CT-M3</secondary_id>
    <nct_id>NCT00047697</nct_id>
  </id_info>
  <brief_title>Donepezil HCl &amp; Cognitive Deficits in Autism</brief_title>
  <official_title>Donepezil HCl: Treating Cognitive Deficits in Autism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This 11-week study will examine the safety and effectiveness of the medication donepezil
      (AriceptÂ®) compared to placebo for treating cognitive deficits in children and adolescents
      with Autism Spectrum Disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Children with autism spectrum disorder (ASD) often have impaired communication, problems with
      social interaction, and repetitive and stereotyped patterns of behavior. While most research
      has attempted to treat the behavioral deficits commonly associated with ASD, few studies have
      attempted to improve the core features of this disorder. A recent study found that donepezil
      HCl helped to improve speech production, attention span, and ability to express emotions in a
      group of children with autism. This study will provide an opportunity to conduct further
      testing of the effects of donepezil HCl on the cognitive deficits presumed to underlie the
      core features of ASD.

      This study begins at Week 1 with a baseline assessment. Participants are then randomly
      assigned to either donepezil HCl or placebo. Participants will start with either a 5mg/day
      dose of donepezil HCl or placebo followed by a cognitive assessment after 4 weeks on this
      dose. Participants will then have their dose increased to 10mg/day. Another cognitive
      assessment will be given after 4 weeks on this dose.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date type="Actual">August 2006</completion_date>
  <primary_completion_date type="Actual">August 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cognitive Assessment: TMT</measure>
    <time_frame>8 weeks</time_frame>
    <description>TMT: Trial-Making Test. Time (sec) Range: 0 - 300. Lower = better</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cognitive Assessment: EOWVT Standard Score</measure>
    <time_frame>8 weeks</time_frame>
    <description>Expressive One Word Vocabulary Test (standard score) Range: 55-140. Higher = better</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cognitive Assessment: CVLT</measure>
    <time_frame>8 weeks</time_frame>
    <description>California Verbal Learning Test (percent of correct answers) Range: 0-100. Higher = better</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Autistic Disorder</condition>
  <arm_group>
    <arm_group_label>Donepezil HCl</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Donepezil HCL 5 mg and 10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donepezil HCl</intervention_name>
    <description>Participants will start with 5 mg per day dose of donepezil HCl, then have their dose increased to 10mg per day after 4 weeks.</description>
    <arm_group_label>Donepezil HCl</arm_group_label>
    <other_name>Aricept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo used in placed of Donepezil HCL</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Autism Spectrum Disorder (ASD)

          -  Asperger's Disorder

          -  IQ of 75 or above

          -  Baseline assessment tests within the acceptable range

        Exclusion Criteria:

          -  Bipolar disorder, schizophrenia, schizoaffective disorder, or psychotic disorder

          -  Seizure disorder requiring the use of anticonvulsant medications

          -  Congenital rubella, cytomegalovirus, or tuberous sclerosis

          -  Certain medications prescribed for management of behavior (please contact the
             investigator for a complete list)

          -  Medications/preparations that are known to interact with donepezil HCl

          -  Significant medical illness, endocrinopathies, cardiovascular disease, or severe
             chronic malnutrition

          -  Pregnancy or sexually active females not using a reliable method of contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin L. Handen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh, School of Medicine, Department of Psychiatry</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Western Psychiatric Institute &amp; Clinic</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2002</study_first_submitted>
  <study_first_submitted_qc>October 15, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2002</study_first_posted>
  <results_first_submitted>March 30, 2015</results_first_submitted>
  <results_first_submitted_qc>September 7, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 5, 2017</results_first_posted>
  <last_update_submitted>September 7, 2017</last_update_submitted>
  <last_update_submitted_qc>September 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Benjamin L Handen, PhD, BCBA-D</investigator_full_name>
    <investigator_title>Assistant Professor of Psychiatry &amp; Pediatric</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Cognition Disorders</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>We have no specific plan to share data at this time.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Donepezil HCL</title>
          <description>Subjects placed on 5 and 10 mg of donepezil</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Subjects placed on 5 mg or 10 mg of placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Donepezil HCL</title>
          <description>Donepezil HCl: Participants will start with 5 mg per day dose of donepezil HCl, then have their dose increased to 10mg per day after 4 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants will start with 5 mg/day of placebo, then have their doses increased to 10 mg/day of placebo after 4 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.6" lower_limit="8.7" upper_limit="16.8"/>
                    <measurement group_id="B2" value="11.8" lower_limit="8.1" upper_limit="16.6"/>
                    <measurement group_id="B3" value="11.7" lower_limit="8.1" upper_limit="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cognitive Assessment: TMT</title>
          <description>TMT: Trial-Making Test. Time (sec) Range: 0 - 300. Lower = better</description>
          <units>Seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="123.6" spread="56.5"/>
                    <measurement group_id="B2" value="154.9" spread="77.8"/>
                    <measurement group_id="B3" value="138.3" spread="66.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cognitive Assessment: EOWVT Standard score</title>
          <description>Expressive One Word Vocabulary Test (standard score) Range: 55-140. Higher = better</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104.6" spread="22.4"/>
                    <measurement group_id="B2" value="108.7" spread="17.0"/>
                    <measurement group_id="B3" value="106.5" spread="19.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cognitive Assessment: CVLT</title>
          <description>California Verbal Learning Test (percent of correct answers) Range: 0-100. Higher = better</description>
          <units>Correct answers, percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.7" spread="14.1"/>
                    <measurement group_id="B2" value="47.1" spread="10.3"/>
                    <measurement group_id="B3" value="43.7" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cognitive Assessment: TMT</title>
        <description>TMT: Trial-Making Test. Time (sec) Range: 0 - 300. Lower = better</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Donepezil HCl</title>
            <description>Participants will start with 5 mg per day dose of donepezil HCl, then have their dose increased to 10mg per day after 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo used in placed of Donepezil HCL</description>
          </group>
        </group_list>
        <measure>
          <title>Cognitive Assessment: TMT</title>
          <description>TMT: Trial-Making Test. Time (sec) Range: 0 - 300. Lower = better</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.3" spread="79.1"/>
                    <measurement group_id="O2" value="104.7" spread="53.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cognitive Assessment: EOWVT Standard Score</title>
        <description>Expressive One Word Vocabulary Test (standard score) Range: 55-140. Higher = better</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Donepezil HCl</title>
            <description>Participants will start with 5 mg per day dose of donepezil HCl, then have their dose increased to 10mg per day after 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo used in place of Donepezil HCL</description>
          </group>
        </group_list>
        <measure>
          <title>Cognitive Assessment: EOWVT Standard Score</title>
          <description>Expressive One Word Vocabulary Test (standard score) Range: 55-140. Higher = better</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.7" spread="21.0"/>
                    <measurement group_id="O2" value="114.5" spread="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cognitive Assessment: CVLT</title>
        <description>California Verbal Learning Test (percent of correct answers) Range: 0-100. Higher = better</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Donepezil HCl</title>
            <description>Participants will start with 5 mg per day dose of donepezil HCl, then have their dose increased to 10mg per day after 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo used in place of Donepezil HCL</description>
          </group>
        </group_list>
        <measure>
          <title>Cognitive Assessment: CVLT</title>
          <description>California Verbal Learning Test (percent of correct answers) Range: 0-100. Higher = better</description>
          <units>percentage of correct answers</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.2" spread="11.0"/>
                    <measurement group_id="O2" value="51.3" spread="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs were collected for 10 weeks (and for longer if a subject had an active AE at the end of the 10-week trial).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Donepezil HCL</title>
          <description>5 mg of donepezil for 4 weeks, followed by 10 mg of donepezil for 6 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo substituted for Donepezil HCL</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The trial may not have been long enough to obtain clinically significant effects</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Benjamin L. Handen, PhD</name_or_title>
      <organization>University of Pittsburgh</organization>
      <phone>412-235-5445</phone>
      <email>handenbl@upmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

